N/A N=306 Health Services Research

Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)

HIV · Hepatitis C · Opioid-use Disorder · Injection Drug Use

Bottom Line

View on ClinicalTrials.gov: NCT04427202 ↗

Enrolled (actual)

306

Serious AEs

1.6%

Results posted

Dec 2024

Primary outcome: Primary: Total Participants Who Received Referrals to the Harm Reduction Services Organization — 121 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Referral to harm reduction services (Behavioral)
Age: Pediatric, Adult, Older Adult · 15+ yrs
Sex: All
Sponsor: University of Chicago
Primary completion: Aug 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Total Participants Who Received Referrals to the Harm Reduction Services Organization	121	—
SECONDARY Number of Locations Where Participants Received Most of Syringes or Needles	92	—
SECONDARY Number of Times Sterile Syringes and/or Equipment Obtained From an Intervention	2.5	—
SECONDARY Number of Times Participants Used a Syringe or Needle That They Knew Was Used by Somebody Else	0.9	—
SECONDARY Number of Times Participants Used a Cotton, Cooker, Spoon, or Water for Rinsing or Mixing That They Knew Was Used by Somebody Else	2.5	—
SECONDARY Number of Times Participants Let Someone Else Use a Cotton, Cooker, Spoon, or Water for Rinsing or Mixing After They Used it	2.3	—
SECONDARY Number of Participants With Drive Time Less Than 30 Minutes to Nearest Syringe or Needle Exchange	148	—
SECONDARY Number of Participants That Currently Have Naloxone	93	—
SECONDARY Number of Participants Who Received Substance Use Disorders (SUD) Treatment Referrals	102	—
SECONDARY Total Number of Participants Who Received an HIV Screening	288	—
SECONDARY Total Number of Participants Who Received an HCV Screening	213	—
SECONDARY Number of Participants With Knowledge of PrEP	155	—
SECONDARY Number of Participants Diagnosed With HIV Who Have Access to HIV Care	—	—
SECONDARY Number of Participants Diagnosed With HCV Who Have Access to HCV Care	11	—
SECONDARY Number of Times a Participant Engaged in Condomless Sex (Vaginal or Anal)	9.9	—

Summary

This study will evaluate the referral to harm reduction services (HRS) including syringe services, naloxone overdose prevention, substance use treatment referral, HIV, HCV, and STD testing and referral and linkage to care through capacity building of existing programs through client services data.

Eligibility Criteria

Inclusion Criteria

15 years of age and older
Injected any drug in the past 30 days
Used any opioids non-medically in the past 30 days
English speaking
Able to provide informed consent at the time of the study visit

Exclusion Criteria

Less than 15 years of age
Not injected any drug in the past 30 days
Not used any opioids non-medically in past 30 days
Non-English speaking
Has not injected any opioid drug to get high in the past 30 days
Unable to provide informed consent at the time of the study visit

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04427202). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.